Jun Ying

High Impact

Professor

UAMS

Formerly Arkansas Affiliated with UAMS through 2021; recent publications list University of Colorado Anschutz, University of Cincinnati.

39 h-index 143 pubs 4,472 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 50 institutions in 6 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Jun Ying's research investigates the application of computational methods and statistical modeling to address diverse health-related questions. His work has explored the correlation between imaging characteristics and histological outcomes in prostate cancer, the validation of case definitions for immune reconstitution syndrome in HIV patients, and the prediction of aspiration risk in individuals with ischemic stroke. Ying has also examined the effectiveness of surveillance strategies for hepatocellular carcinoma in clinical practice within the United States.

Further extending his research interests, Ying has contributed to studies on the association between environmental factors and health outcomes, including the relationship between agrichemicals in surface water and birth defects. He has also investigated the development and application of analytical techniques for determining specific compounds in biological and food samples, such as chloramphenicol and thiamphenicol in honey using liquid-liquid microextraction and high-performance liquid chromatography. His recent work includes the use of machine learning models to predict hearing outcomes in sudden sensorineural hearing loss.

Metrics

h-index: 39
Publications: 143
Citations: 4,472

Positions

Professor 2023–present

Anschutz Medical Campus, University of Colorado Family Medicine ORCID
Professor

University of Arkansas for Medical Sciences ORCID

Selected Publications

Sézary Syndrome Biomarker, T Cell Transcription Factors and Cytokine Genes Provide Novel Insight into Response During Mogamulizumab Treatment (2026)

Cancers DOI OpenAlex
Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025)

Current Oncology DOI OpenAlex
Years of Potential Life Lost for Children and Adults With Congenital Heart Defects: United States, 2007 to 2017 (2025)

Journal of the American Heart Association 1 citation DOI OpenAlex
Bias in Prediction Models to Identify Patients With Colorectal Cancer at High Risk for Readmission After Resection (2024)

JCO Clinical Cancer Informatics 4 citations DOI OpenAlex
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)

Translational Lung Cancer Research 1 citation DOI OpenAlex
Maximizing Readmission Reduction in Colon Cancer Patients (2023)

Journal of Surgical Research 2 citations DOI OpenAlex
A Prospective Study Measuring Resident and Faculty Contour Concordance: A Potential Tool for Quantitative Assessment of Residents’ Performance in Contouring and Target Delineation in Radiation Oncology Residency (2023)

Journal of the American College of Radiology 6 citations DOI OpenAlex
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023)

JCO Oncology Practice 13 citations DOI OpenAlex